Literature DB >> 21633829

[Basal cell carcinomas in radiotherapy-treated port wine stains. An ideal indication for Mohs surgery].

E Sattler1, H-C Räwer, M Mühlstädt, T Ruzicka, W Burgdorf, C Kunte.   

Abstract

BACKGROUND: Early treatment of port wine stains with ionizing radiation can lead to the development of often multifocal basal cell carcinomas (BCC) after decades. In most cases it is clinically impossible to distinguish between the tumor and the underlying vascular malformation and to decide where to set surgical margins. PATIENTS AND METHODS: We report on a series of three patients with BCC overlying a port wine stain that had previously been treated with radiation therapy in early childhood. In all patients Mohs surgery was performed to insure complete excision of the BCC.
RESULTS: In our patients, development of BCC occurred about 20 to 40 years after radiation therapy. Clinically - without the help of Mohs surgery - the borders of the BCC could not have been detected due to the underlying nevi flammei in all cases.
CONCLUSIONS: BCC overlying a port wine stain previously treated with radiation therapy is a rare but ideal indication for Mohs surgery. In addition we recommend regular clinical follow-ups to detect recurrent or additional BCC as early as possible.

Entities:  

Mesh:

Year:  2011        PMID: 21633829     DOI: 10.1007/s00105-011-2188-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  25 in total

1.  Multiple basal cell carcinomas arising in radiotherapy-treated nevus flammeus: early detection facilitated by 595-nm pulsed dye laser.

Authors:  Kjell M Kaune; Ellen Haas; Timo Buhl; Michael P Schön; Markus Zutt
Journal:  Eur J Dermatol       Date:  2010-04-19       Impact factor: 3.328

Review 2.  Role of laser therapy in pediatric patients.

Authors:  A Jay Burns; J Alberto Navarro
Journal:  Plast Reconstr Surg       Date:  2009-07       Impact factor: 4.730

3.  Three cases of multiple basal cell carcinoma arising in port-wine stains previously treated with thorium X.

Authors:  M Shah; F M Lewis; I R Palmer
Journal:  Br J Dermatol       Date:  1996-11       Impact factor: 9.302

4.  Clinical experience in the treatment of different vascular lesions using a neodymium-doped yttrium aluminum garnet laser.

Authors:  Ekrem Civas; Erol Koc; Berna Aksoy; Hasan Mete Aksoy
Journal:  Dermatol Surg       Date:  2009-12       Impact factor: 3.398

5.  Combined benzoporphyrin derivative monoacid ring photodynamic therapy and pulsed dye laser for port wine stain birthmarks.

Authors:  Joshua A Tournas; Jennifer Lai; Anne Truitt; Y C Huang; Kathryn E Osann; Bernard Choi; Kristen M Kelly
Journal:  Photodiagnosis Photodyn Ther       Date:  2009-11-12       Impact factor: 3.631

Review 6.  Photodynamic therapy in treatment of port wine stain birthmarks--recent progress.

Authors:  Kai-Hua Yuan; Qin Li; Wen-Lin Yu; Zheng Huang
Journal:  Photodiagnosis Photodyn Ther       Date:  2009-09-10       Impact factor: 3.631

7.  Multifocal basal cell carcinoma developing in a facial port wine stain treated with argon and pulsed dye laser: a possible role for previous radiotherapy.

Authors:  Zaid F Jasim; Wai K Woo; Maureen Y Walsh; Julian M Handley
Journal:  Dermatol Surg       Date:  2004-08       Impact factor: 3.398

8.  Dermatology - a surgical discipline - as exemplified by surgical procedures at the Hospital of Munich Thalkirchner Strasse.

Authors:  Christian Kunte; Wolfgang Pfützner; Karin Kerschenlohr; Birger Konz
Journal:  J Dtsch Dermatol Ges       Date:  2008-07       Impact factor: 5.584

9.  Pulsed dye laser vs. intense pulsed light for port-wine stains: a randomized side-by-side trial with blinded response evaluation.

Authors:  A Faurschou; K Togsverd-Bo; C Zachariae; M Haedersdal
Journal:  Br J Dermatol       Date:  2008-12-11       Impact factor: 9.302

10.  Treatment of hypertrophic and resistant port wine stains with a 755 nm laser: a case series of 20 patients.

Authors:  Leonid Izikson; J Stuart Nelson; R Rox Anderson
Journal:  Lasers Surg Med       Date:  2009-08       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.